Biotech Analysts discuss improving Cystic Fibrosis Treatments with Next-Gen Modulators (SION, VRTX) on an Analyst/Industry conference call to be held on May 20.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Yazdi Reiterates Buy on Sionna, Keeps $58 Price Target Ahead of High-Impact 2026 SION-719 Readout
- Sionna Therapeutics reports Q1 EPS (60c), consensus (50c)
- Vertex Pharmaceuticals price target lowered to $572 from $577 at Bernstein
- Sionna Therapeutics initiated with an Outperform at Wedbush
- Sionna Therapeutics price target raised to $63 from $52 at JonesResearch